Celator Pharmaceuticals Inc. (NASDAQ:CPXX) was down 0% on Friday . The stock traded as low as $30.23 and last traded at $30.24, with a volume of 274,314 shares. The stock had previously closed at $30.25.

A number of equities research analysts have commented on CPXX shares. Janney Montgomery Scott started coverage on shares of Celator Pharmaceuticals in a report on Tuesday, March 15th. They issued a “buy” rating and a $13.00 price target for the company. Roth Capital raised their price target on shares of Celator Pharmaceuticals from $18.00 to $22.00 and gave the stock a “buy” rating in a report on Tuesday, March 15th. Stifel Nicolaus started coverage on shares of Celator Pharmaceuticals in a report on Friday, April 22nd. They issued a “buy” rating and a $23.00 price target for the company. Needham & Company LLC started coverage on shares of Celator Pharmaceuticals in a report on Tuesday, April 12th. They issued a “buy” rating and a $24.00 price target for the company. Finally, HC Wainwright raised their price target on shares of Celator Pharmaceuticals to $20.00 and gave the stock a “buy” rating in a report on Tuesday, March 15th. Four analysts have rated the stock with a hold rating and three have given a buy rating to the company. The company currently has an average rating of “Hold” and a consensus target price of $18.67.

The firm’s market capitalization is $1.28 billion. The stock’s 50-day moving average price is $27.92 and its 200 day moving average price is $12.13.

Celator Pharmaceuticals (NASDAQ:CPXX) last announced its quarterly earnings data on Tuesday, May 10th. The company reported ($0.16) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.15) by $0.01. On average, equities analysts anticipate that Celator Pharmaceuticals Inc. will post ($0.62) EPS for the current fiscal year.

Celator Pharmaceuticals, Inc is an oncology-focused biopharmaceutical company. The Company is engaged in developing products to improve patient outcomes in cancer. The Company’s technology platform, CombiPlex, enables the design and evaluation of optimized combinations incorporating traditional chemotherapies, as well as molecularly targeted agents to deliver anti-cancer activity.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.